catridecacog
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Congenital Bleeding Disorder
Conditions
Congenital Bleeding Disorder, Congenital FXIII Deficiency
Trial Timeline
Aug 1, 2008 → Apr 1, 2010
NCT ID
NCT00713648About catridecacog
catridecacog is a phase 3 stage product being developed by Novo Nordisk for Congenital Bleeding Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT00713648. Target conditions include Congenital Bleeding Disorder, Congenital FXIII Deficiency.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01862367 | Pre-clinical | Completed |
| NCT01253811 | Phase 3 | Completed |
| NCT01230021 | Phase 3 | Completed |
| NCT00978380 | Phase 3 | Completed |
| NCT00713648 | Phase 3 | Completed |
| NCT00056589 | Phase 1 | Completed |
Competing Products
20 competing products in Congenital Bleeding Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Tideglusib | AMO Pharma | Pre-clinical | 15 |
| Tideglusib + Placebo | AMO Pharma | Phase 2/3 | 57 |
| Tideglusib | AMO Pharma | Phase 2/3 | 57 |
| EDIT-101 | Editas Medicine | Phase 1/2 | 33 |
| Tildacerfont/Placebo | Spruce Biosciences | Phase 2 | 44 |
| SPR001 | Spruce Biosciences | Phase 2 | 44 |
| SPR001 | Spruce Biosciences | Phase 2 | 44 |
| Tildacerfont/Placebo | Spruce Biosciences | Phase 2 | 44 |
| Tildacerfont | Spruce Biosciences | Phase 2 | 44 |
| KW-3357 | Kyowa Kirin | Phase 1 | 33 |
| Pasireotide 0.6Mg Solution for Injection + Saline Solution | Novartis | Phase 2 | 52 |
| Sandostatine LP | Novartis | Phase 2 | 52 |
| mycophenolate mofetil | Roche | Phase 1 | 33 |
| turoctocog alfa + turoctocog alfa | Novo Nordisk | Phase 3 | 76 |
| catridecacog + recombinant factor XIII | Novo Nordisk | Phase 1 | 32 |
| activated recombinant human factor VII | Novo Nordisk | Phase 2 | 51 |
| turoctocog alfa pegol | Novo Nordisk | Phase 3 | 76 |
| recombinant factor XIII | Novo Nordisk | Pre-clinical | 22 |
| activated recombinant human factor VII, long acting + activated recombinant human factor VII, long acting | Novo Nordisk | Phase 1 | 32 |
| Advate® + turoctocog alfa | Novo Nordisk | Phase 1 | 32 |